The Medical Letter on Drugs and Therapeutics
Pertuzumab (Perjeta) for HER2-Positive Metastatic Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Pertuzumab (Perjeta – Roche/Genentech), a humanized monoclonal antibody, has been approved by the FDA for use in combination with trastuzumab (Herceptin) and docetaxel (Taxotere, and others) for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.

MECHANISM OF ACTION — HER2, a transmembrane receptor protein involved in normal cell growth, is overexpressed in about 15-20% of breast cancers.1,2 Increased amounts of HER2 protein on the surface of breast cancer cells contribute to cancer cell growth and survival, and are typically associated with more aggressive disease and reduced survival.3 Pertuzumab binds to the HER2 receptor and inhibits its pairing (dimerization) with other HER receptors on the surface of cells, resulting in a blockade of HER2 signaling, cell ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Pertuzumab (Perjeta) for HER2-Positive Metastatic Breast Cancer
Article code: 1395c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian